Managing Toxicity of Intravesical Therapy

Joachim Mathes; Tilman Todenhöfer

doi:10.1016/j.euf.2018.09.009

Managing Toxicity of Intravesical Therapy

Eur Urol Focus. 2018 Jul;4(4):464-467. doi: 10.1016/j.euf.2018.09.009. Epub 2018 Oct 25.

Authors

Joachim Mathes¹, Tilman Todenhöfer²

Affiliations

¹ Department of Urology, Eberhard-Karls-University, Tübingen, Germany.
² Department of Urology, Eberhard-Karls-University, Tübingen, Germany. Electronic address: tilman.todenhoefer@med.uni-tuebingen.de.

PMID: 30473130
DOI: 10.1016/j.euf.2018.09.009

Abstract

Intravesical therapies have shown positive effects both on recurrence and progression of non-muscle-invasive bladder cancer. However, more than 50% of patients experience untoward side effects associated with treatment. In order to reduce the rate of patients who discontinue treatment due to side effects, prevention and effective management of treatment-related toxicity is essential.

Keywords: BCG; Bladder cancer; Mitomycin; Side effects; Urothelial carcinoma.

MeSH terms

Adjuvants, Immunologic / administration & dosage
Adjuvants, Immunologic / adverse effects
Administration, Intravesical*
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects
BCG Vaccine* / administration & dosage
BCG Vaccine* / adverse effects
Drug-Related Side Effects and Adverse Reactions* / classification
Drug-Related Side Effects and Adverse Reactions* / diagnosis
Drug-Related Side Effects and Adverse Reactions* / prevention & control
Drug-Related Side Effects and Adverse Reactions* / therapy
Humans
Mitomycin* / administration & dosage
Mitomycin* / adverse effects
Severity of Illness Index
Urinary Bladder Neoplasms* / drug therapy
Urinary Bladder Neoplasms* / pathology

Substances

Adjuvants, Immunologic
Antineoplastic Agents
BCG Vaccine
Mitomycin